Jana van Wie, MD
Family Medicine · Grand Island, NENPI 1720062458
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $747 and has fallen 66.0% since, to $254 in 2025.
Across 160 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$596
- Lilly USA, LLC$235
- Pfizer$151
- Novo Nordisk$139
- Mallinckrodt Hospital Products Inc.$133
- Amgen$108
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,54599%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $596 |
| Lilly USA, LLC | 15 | $235 |
| Pfizer | 10 | $151 |
| Novo Nordisk | 10 | $139 |
| Mallinckrodt Hospital Products Inc. | 6 | $133 |
| Amgen | 8 | $108 |
| Gilead | 5 | $102 |
| Novartis | 7 | $101 |
| Mylan Specialty L.p. | 5 | $89 |
| AstraZeneca(2 entities) | 5 | $75 |
| Exact Sciences | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $60 |
| Travere Therapeutics, Inc. | 3 | $55 |
| Astellas Pharma US Inc | 3 | $52 |
| Biohaven Pharmaceuticals, Inc. | 3 | $48 |
| GSK | 3 | $42 |
| Dexcom, Inc. | 3 | $41 |
| Medtronic | 2 | $39 |
| Johnson & Johnson | 2 | $37 |
| Biogen | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Bayer | 2 | $29 |
| Sanofi | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Merck | 2 | $24 |
| Abbott | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$2,564 in reported general payments places this provider in the 80th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 54 | $59,614 |
| OzempicSemaglutide | 52 | $48,137 |
| EliquisApixaban | 48 | $38,732 |
| MounjaroTirzepatide | 31 | $36,044 |
| LinzessLinaclotide | 36 | $22,456 |
| FarxigaDapagliflozin Propanediol | 16 | $21,087 |
| JanuviaSitagliptin Phosphate | 23 | $20,732 |
| RybelsusSemaglutide | 14 | $15,343 |
| XareltoRivaroxaban | 25 | $15,293 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $11,330 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 35 | $10,507 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,486 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 162 | $7,063 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 29 | $6,073 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $5,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $139 | $63,48066 claims |
| PfizerEliquis, Abrysvo | $151 | $49,23983 claims |
| Lilly USA, LLCMounjaro | $235 | $36,04431 claims |
| MerckJanuvia, Janumet Xr | $24 | $25,91337 claims |
| AbbVieLinzess | $596 | $22,45636 claims |
| AstraZenecaFarxiga | $75 | $21,08716 claims |
| Johnson & JohnsonXarelto | $37 | $15,29325 claims |
| GSKTrelegy Ellipta, Shingrix | $42 | $13,55941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Grand Island
- James OmelGrand Island$67K
- Michael IsraelLincoln$375K
- Francisco DozonNorfolk$238K
- Randy KohlLincoln$67K
- Gerard StanleyOmaha$50K
- Jared KramerSt Paul$41K
- Randolph WaldmanHebron$27K
- Brian FinleyBellevue$20K
- William FitzgibbonsElkhorn$18K
- Michael BrennerSouth Sioux City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.